The University of Washington School of Medicine will study pharmacogenetics in patients with COVID-19.<\/p>\n
It will work with Washington, D.C.-based Vanda Pharmaceuticals to collect whole-genome sequencing data from more than 1,000 patients with coronavirus infection. The two will sequence the viral genomes to explore host susceptibility, clinical outcomes of whole-genome sequencing, host-virus interactions, and disease severity.<\/p>\n
\"We believe this collaboration will help answer critical questions and hopefully outcomes in the fight against COVID-19,\" Alex Greninger, assistant director of the virology division at the UW School of Medicine, said in a statement.<\/p>\n
Financial and other details of the collaboration were not disclosed.<\/p>\n
The collaboration with UW's virology lab will be part of a larger program from Vanda, dubbed Calypso, to study the role of human genetic variation in SARS-CoV-2 infection and COVID-19 disease progression.<\/p>\n
\"The study has the potential to provide new insights into virus-host interactions that could lead to more effective public health strategies and the design and development of vaccines and therapeutics,\" Sandra Smieszek, head of genetics at Vanda, said in a statement. \"With the vast amount of data we expect to collect, the team will aim to discern the factors associated with severity and other critical, clinical characteristics of the infected individuals.\"<\/p>\n
Vanda on Wednesday also announced it was working with Northwell Health's research arm to conduct a clinical trial of a drug to treat severe pneumonia in COVID-19 patients.<\/p>\n
This story first appeared in our sister publication, Genomeweb.<\/p>\n
<\/p>\n
Go here to read the rest: The University of Washington School of Medicine will study pharmacogenetics in patients with COVID-19. Continue reading
\nUniversity of Washington to study COVID-19 pharmacogenetics - ModernHealthcare.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"